Jun 7, 2016
Celgene Corporation has announced the result of a study comparing treatment patterns, healthcare costs and overall survival between African American and Caucasian Medicare beneficiaries with recently diagnosed multiple myeloma. The study discussed disparities observed in treatment between the two studied populations and the impact of these disparities on outcomes in patient.
As said by Dr. Manali Patel of the Stanford Cancer Center and an investigator in the study: “African Americans may be more at risk for developing multiple myeloma than Caucasians, however, they often can have a better prognosis when they get the proper care. Through studies like this, we are trying to better understand potential modifiable drivers of these disparities to improve outcomes for African Americans living with multiple myeloma.”
The study evaluated 2,200 Caucasian and 536 African American multiple myeloma patients in the Surveillance, Epidemiology, and End Results Program (SEER) Medicare database from 2007 and 2011. The study found that elderly African Americans with multiple myeloma had lower rates of receiving access to autologous stem cell transplant and novel combination therapies compared to Caucasians with the same disease.
“Treatment disparities exist between African American and Caucasian patients suffering from multiple myeloma. At Celgene, we believe it is imperative to improve education, awareness and treatment access among African Americans, particularly since they are more predisposed to being diagnosed with the disease,” said Dr. Mohamad Hussein, Vice President of Global Medical Affairs for Celgene.